Singling out the Heart: Revolutionizing Heart Failure by Harnessing Translational Technologies.
Singling out the Heart: Revolutionizing Heart Failure by Harnessing Translational Technologies.
复制标题
挑选心脏：利用转化技术彻底改变心力衰竭。
DOI：
10.1016/j.cardfail.2023.04.005
复制
发表时间：
2023
影响因子：
6
通讯作者：
Randhawa,VarinderKaur
中科院分区：
文献类型：
--
作者：
Kamdar,Forum;Randhawa,VarinderKaur
心力衰竭 (HF) 影响着全球超过 6400 万人，其中美国有 650 万名成年人 [1, 2]。除了全球患病率不断上升外，心力衰竭还是全球死亡率和发病率的主要原因，导致住院人数增加和巨额医疗支出。尽管针对各种心力衰竭患者的医疗和设备治疗取得了相当大的进步，但心力衰竭的负担仍在继续增加，因此进一步解决心力衰竭的发病机制和治疗是全球的当务之急。心力衰竭是一种复杂且异质性的临床综合征，需要了解潜在的疾病病因、严重程度、充血特征和发病机制，以优化治疗和管理。此外，从全球角度来看，心力衰竭病因的分布因地理区域而异，因此需要进行当地调查以解决该人群独特的心力衰竭特征。除了正在进行的临床工作外，还需要进一步阐明心力衰竭的分子机制，以加速开发新型病因特异性疗法。心力衰竭的转化研究可以在促进心力衰竭的个性化治疗方法方面发挥不可或缺的作用，包括对差异日益明显的特殊人群的护理。
Heart failure (HF) affects over 64 million individuals worldwide, with 6.5 million adults in the United States [1, 2]. In addition to its escalating global prevalence, HF is a leading cause of mortality and morbidity worldwide, resulting in increasing hospitalizations and significant healthcare expenditure. Despite considerable advances in medical and device therapies for patients across the spectrum of HF, the burden of HF continues to grow, thus there is an urgent global priority to further address the pathogenesis and treatment of HF. HF is a complex and heterogeneous clinical syndrome that requires an understanding of the underlying disease etiology, severity, congestive profile, and pathogenesis to optimize treatment and management. Additionally, from a global perspective, the distribution of HF etiologies varies by geographic region, necessitating local investigation to address the unique HF features of that population. In addition to ongoing clinical efforts, further unraveling the molecular mechanisms of HF is needed to accelerate the development of novel etiology-specific therapies. Translational research in HF can play an integral role in facilitating a personalized approach to HF including care of special populations where differences are increasingly documented.